Feline Chronic Enteropathy vs Lymphoma: Diagnosis

Bottom line

Distinguishing feline lymphoplasmacytic enteritis (LPE) from low-grade intestinal T-cell lymphoma (LGITL) requires an integrated assessment rather than a positive clonality result or thickened bowel layer alone. The ACVIM consensus places intestinal histology at the center, with immunohistochemistry and clonality testing used in context. [1] Plan which segments and tissue features must be sampled before choosing the biopsy route.

Establish an intestinal syndrome without assuming its cause

Clinical signs and routine laboratory findings overlap between LPE and LGITL. A prospective cohort found some features associated with LGITL, including altered jejunal lymph nodes and small-volume abdominal effusion, but still required comprehensive tissue and phenotypic assessment for diagnosis. [2]

Review the dietary and medication history, weight and muscle trajectory, actual intake and previous test results. Record which extragastrointestinal, infectious and metabolic explanations have been investigated and which remain plausible. A historical label of inflammatory bowel disease should not close the differential when the clinical course changes.

The feline cholangitis workflow addresses a separate concurrent-disease question. Do not use a triaditis label to assume that biliary and intestinal findings have the same cause or should receive identical treatment.

Use ultrasound to map the next procedure

The consensus considers abdominal ultrasound important for assessing the bowel, associated organs, lymph nodes and suitable sampling targets. It also describes substantial overlap between LPE and LGITL in bowel-wall and layering changes; an unremarkable examination does not exclude clinically relevant intestinal disease. [1]

In the prospective clinical-imaging cohort, many ultrasonographic variables did not differ between groups. Rounded jejunal nodes and effusion increased suspicion in that population, but subjective assessment, small sample size and retrospective review of stored ultrasound images limited interpretation. These were probability modifiers, not a replacement for biopsy. [2]

Ask the imaging report to distinguish a diffuse mucosal question from a focal mass, inaccessible segment or extraintestinal target. The procedure should be designed around the unresolved lesion rather than around an assumption that all chronic enteropathy requires the same sampling route.

Select segments and specimen quality before selecting a route

Endoscopy allows direct mucosal inspection and targeted sampling with less invasiveness. Surgery permits jejunal, full-thickness and extraintestinal sampling but carries operative and healing risks. Both approaches can fail through inadequate sample number, damaged tissue or poor orientation; a visually large full-thickness wedge may contain little interpretable mucosa. [1]

A prospective distribution study found heterogeneous lesions and supported collecting both duodenal and ileal samples. However, most ileal specimens were obtained surgically, and the authors state that comparative accuracy of endoscopic and surgical ileal sampling remained unknown. Its favorable combined-segment result must not be presented as proof that purely endoscopic sampling always detects LGITL. [3]

Discuss the intended segments, accessible lesions, tissue handling and pathology requirements before anesthesia. If only part of the planned intestine can be sampled, document that limitation and its consequence for a negative or ambiguous result. Do not interpret “no lymphoma in this specimen” as a statement about every unsampled segment.

Integrate histology, immunophenotype and clonality

Histology assesses architecture, cell morphology and infiltration pattern. Immunohistochemistry helps characterize the cellular population and is an important ancillary tool in ambiguous cases, but it does not provide absolute separation in every cat. The consensus recognizes that inflammatory and neoplastic populations can coexist. [1]

PARR assesses antigen-receptor rearrangements, not malignant behavior itself. The consensus describes biological clonal expansion as well as technical limitations including DNA quality, limited primer coverage and pseudoclonality. It specifically advises against reclassifying a case from clonality alone. [1]

When results disagree, request an integrated pathology discussion: what finding supports malignancy, is the sample representative, and is the result reproducible and concordant with morphology? Additional review or sampling should answer a defined uncertainty rather than simply repeat a molecular result until it fits the initial impression.

Interpret incidental abnormalities cautiously

In a cohort of clinically healthy client-owned cats, histology, immunohistochemistry and clonality frequently produced abnormal or lymphoma-like interpretations, often without apparent clinical relevance during follow-up. The investigators questioned how well existing diagnostic metrics applied to the general feline population. [4]

This does not prove that all abnormalities are harmless or that biopsy is unnecessary in a symptomatic cat. It warns against interpreting a tissue test without the patient's phenotype and the uncertainty of the reference standard. Avoid converting a laboratory classification alone into a precise survival prediction or a chemotherapy instruction.

Link the diagnosis to a practical management decision

The consensus argues that a comprehensive evaluation can exclude other intestinal disorders and help refine prognosis and treatment strategy, while acknowledging that ambiguous cases remain. [1] Explain whether the present result is definitive, strongly supported or still indeterminate, and what a further test would change.

Maintain nutrition while diagnostic decisions proceed. The hepatic lipidosis nutritional workflow addresses assisted feeding and metabolic monitoring when that complication is supported. Record treatment exposure and clinical response alongside the final pathology interpretation; improvement alone should not rewrite an uncertain tissue diagnosis.

Frequently Asked Questions

Can chronic vomiting or weight loss distinguish inflammation from lymphoma?

Not reliably. Clinical signs and routine laboratory findings overlap between lymphoplasmacytic enteritis and low-grade intestinal T-cell lymphoma. [2]

Does muscularis thickening establish low-grade intestinal lymphoma?

No. The ACVIM consensus describes substantial overlap in intestinal ultrasonographic changes between inflammatory and low-grade neoplastic disease. [1]

Is histology needed to distinguish LPE from LGITL?

Yes. The consensus requires intestinal histology, interpreted with clinical information and ancillary testing when necessary. [1]

Did combined-segment sampling prove purely endoscopic biopsy always sufficient?

No. The prospective distribution study supported sampling duodenum and ileum, but most ileal samples were surgical and comparative endoscopic-versus-surgical accuracy remained unknown. [3]

Does a clonal PARR result alone establish malignancy?

No. The consensus cautions against reclassification from clonality alone and recommends integrating morphology, immunophenotype and clinical context. [1]

Can abnormal biopsy tests occur in clinically healthy cats?

Yes. The healthy-cat cohort found histological and clonality abnormalities without apparent clinical relevance in many cats during follow-up; it did not establish that every clonal finding is benign. [4]

Does inflammatory infiltration exclude concurrent LGITL?

No. The prospective distribution study found concurrent inflammatory infiltrates in intestinal segments with neoplastic lymphocytes. [3]